Business Wire

W Hotels Worldwide to Make Scottish Debut in 2021

Del

Starwood Hotels & Resorts Worldwide, Inc. (NYSE:HOT) today announced it will debut the iconic W Hotels brand in Scotland with W Edinburgh. Opening in 2021 and set to reinvigorate the city’s traditional hospitality scene, the hotel will be part of TH Real Estate’s Edinburgh St James scheme, which is set to complete in 2020. Designed by award-winning architecture and interior design practice Jestico + Whiles, in conjunction with Allan Murray Architects, the 12-story building will feature a unique façade crafted from a winding steel ‘ribbon’. W Edinburgh will form the centerpiece of the 1.7 million square foot development, which will incorporate a vibrant blend of retail, entertainment, leisure and residential apartments, further reinforcing the city’s reputation as a booming cosmopolitan capital.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160719005603/en/

A rendering of the forthcoming W Edinburgh (Graphic: Business Wire)

A rendering of the forthcoming W Edinburgh (Graphic: Business Wire)

“As an established business hub with a thriving global tourism industry, we are confident that there will be a huge appetite for our innovative lifestyle brand in the Scottish capital,” said Michael Wale, President, Starwood Hotels & Resorts, Europe, Africa and Middle East. “W Edinburgh’s location at the pulsing heart of the new Edinburgh St James development, combined with its innovative design, contemporary interiors and the W brand’s signature programming, will create the perfect setting for the second W hotel in the United Kingdom.”

W Edinburgh will redefine the city’s hospitality landscape with its modern design, signature amenities and a full calendar of W Happenings showcasing what’s new in design, fashion and music. Guests will also be treated to the brand’s iconic Whatever/Whenever® service philosophy that delivers whatever they want, whenever they want it.

The hotel will offer 214 stylish guestrooms, including 20 suites and one Extreme Wow Suite (the W brand’s interpretation of the Presidential Suite). The rooftop will feature a buzzing destination bar and outdoor terrace, offering guests and locals 360-degree panoramic views of the historic skyline, along with a cutting-edge approach to cocktails and cuisine. Other areas will include W Lounge (the W brand’s energetic spin on the hotel lobby), a signature restaurant, FIT® - the ultimate workout facility, and an AWAY® Spa offering the W Hotels brand’s signature health and lifestyle experiences. An ideal venue for events, W Edinburgh will provide 2,450 square feet of ultra-modern event space.

Stephen Wicks, Director of Shopping Centres at TH Real Estate, said, “From the outset, our intention has been to secure a truly world class hotel operator for Edinburgh St James, complementing the rest of the development and forming an integral part of the scheme’s vibrant offer. We are delighted to have finalised this deal with Starwood Hotels and Resorts and to be welcoming such an iconic and established brand as W Hotels to Scotland for the very first time.”

The Edinburgh St James development will see the shopping center currently on site replaced with 850,000 square feet of retail space, a multi-screen cinema and up to 250 new homes, as well as W Edinburgh. The project will support the city’s tourist industry, which contributes an estimated £260m to Edinburgh’s economy each year.

The addition of W Edinburgh to Starwood’s UK portfolio complements the iconic W London - Leicester Square, which opened to great fanfare in 2011 and continues to wow jetsetters from around the world. W loyalists will revel in being able to experience two energetic and unique UK cities within a few hours of travel.

“The fact that W continues to drive growth across the EAME region is testament to the exceptional appeal of the brand to owners and developers. This standout location in the heart of Edinburgh will be a fantastic addition to the W portfolio,” said Karl Bieberach, Vice President Development, Starwood Hotels & Resorts, Europe.

# # #

About W Hotels Worldwide
W Hotels is a contemporary, design-led lifestyle brand and the industry innovator with 49 hotels, including 18 W-branded residences, in the most vibrant cities and exotic destinations around the world. Inspiring, iconic, innovative and influential, W Hotels provides the ultimate in insider access, offering a unique mix of cutting-edge design and passions around fashion, music and entertainment. With over 15 years of proven success, W Hotels is on track to reach 75 hotels by 2020. W Hotels have been announced for Shanghai, Tel Aviv, Goa, Abu Dhabi, Phuket, Dubai, Amman, Jakarta, Panama, Riviera Maya, Muscat, Hainan Island, Suzhou, Changsha, Chengdu, New Delhi, Kuala Lumpur, Shenyang, Marrakech, Brisbane, Aspen and Madrid. For more information, visit whotels.com/theangle or follow Twitter, Instagram and Facebook.

About TH Real Estate
TH Real Estate is an established investment management company, specialising in real estate equity and debt investment worldwide. As one of the largest real estate managers in the world, TH Real Estate has the scale, capital resources and knowledge to provide creative and effective real estate investment solutions for clients. With a focus on the retail, office, logistics, debt and multifamily residential sectors, TH Real Estate emphasises sustainable practices to protect assets and maximise their value. The company is owned by TIAA, the leading provider of financial services in the academic, research, medical, cultural and government fields. TIAA has c.£577bn assets under management* and offers a wide range of financial solutions, including investing, banking, advice and guidance, and retirement services. Launched in April 2014, TH Real Estate has a dedicated global presence with offices across America, Asia and Europe, representing c.£19.7bn* of real estate assets across c.50 funds and mandates. Together with TIAA’s US real estate assets, the global real estate platform of £61.9bn* represents one of the largest real estate investment management enterprises in the world. Its products are managed by specialist teams, which apply their own experience to the management and style of their portfolios. Each team is supported by an experienced senior management team and integrated investment platform, including finance, debt and currency management, performance analytics, client service, fund and transaction structuring, development, sustainability and research. www.threalestate.com *As at 31 December 2015

Contact information

Media Contact:
Aurelie Ternisien, +44 (0)207 290 7107
M +44 (0)7 826 921 753
DIRECTOR OF COMMUNICATIONS, UK & IRELAND
aurelie.ternisien@starwoodhotels.com
www.starwoodmediacentre.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom